Technical Analysis for ALDX - Aldeyra Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical ALDX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | -1.03% | |
| Lower Bollinger Band Touch | Weakness | -1.03% | |
| 200 DMA Resistance | Bearish | -2.36% | |
| 20 DMA Resistance | Bearish | -2.36% | |
| Fell Below 50 DMA | Bearish | -2.36% | |
| Fell Below 200 DMA | Bearish | -3.98% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2019
- Sector: Healthcare
- Industry: Biotechnology
Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.
Medicine Biotechnology Medical Specialties Diseases Organ Systems Autoimmune Diseases Rare Diseases Uveitis Inflammatory Syndromes Systemic Lupus Erythematosus
Medicine Biotechnology Medical Specialties Diseases Organ Systems Autoimmune Diseases Rare Diseases Uveitis Inflammatory Syndromes Systemic Lupus Erythematosus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.79 |
| 52 Week Low | 4.31 |
| Average Volume | 320,291 |
| 200-Day Moving Average | 6.10 |
| 50-Day Moving Average | 5.95 |
| 20-Day Moving Average | 6.09 |
| 10-Day Moving Average | 6.12 |
| Average True Range | 0.33 |
| ADX | 17.69 |
| +DI | 21.48 |
| -DI | 24.75 |
| Chandelier Exit (Long, 3 ATRs ) | 5.88 |
| Chandelier Exit (Short, 3 ATRs ) | 6.59 |
| Upper Bollinger Band | 6.46 |
| Lower Bollinger Band | 5.72 |
| Percent B (%b) | 0.1 |
| BandWidth | 12.15 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.08 |
| MACD Histogram | -0.0587 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.14 | ||||
| Resistance 3 (R3) | 6.16 | 6.06 | 6.08 | ||
| Resistance 2 (R2) | 6.06 | 5.98 | 6.05 | 6.06 | |
| Resistance 1 (R1) | 5.93 | 5.92 | 5.88 | 5.91 | 6.04 |
| Pivot Point | 5.83 | 5.83 | 5.81 | 5.82 | 5.83 |
| Support 1 (S1) | 5.70 | 5.75 | 5.65 | 5.68 | 5.54 |
| Support 2 (S2) | 5.60 | 5.69 | 5.59 | 5.52 | |
| Support 3 (S3) | 5.47 | 5.60 | 5.50 | ||
| Support 4 (S4) | 5.45 |
